公开(公告)号：EP3708587B1

公开(公告)日：2024-05-22

申请号：EP20169645.7

申请日：2016-11-23

IPC分类号： A61K39/00

CPC分类号： A61K38/1774 ,  A61K35/545 ,  C07K14/7051 ,  C07K14/4748 ,  C12N5/0636 ,  C07K2319/0220130101 ,  C07K2319/0320130101 ,  C12N2506/4520130101 ,  C12N2510/0020130101 ,  C07K16/2803 ,  C07K16/3092 ,  C07K2319/3320130101 ,  A61P35/00 ,  A61K39/461 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/4632 ,  A61K39/464402 ,  A61K39/464453 ,  A61K2239/2920230501 ,  A61K39/464417 ,  A61K39/4644 ,  A61K39/464429 ,  C12N5/0638

公开(公告)号：EP3290440B1

公开(公告)日：2024-05-15

申请号：EP16779607.7

申请日：2016-04-14

IPC分类号： C07K16/28 ,  C07K16/30 ,  C07K17/02 ,  A61K39/44 ,  A61P35/00

CPC分类号： A61K39/44 ,  C07K16/2815 ,  C07K16/3069 ,  C07K16/32 ,  A61K2039/50520130101 ,  A61K2039/50720130101 ,  C07K2317/7320130101 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6935 ,  A61K47/6937 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2887 ,  C07K16/3092 ,  C07K2317/3120130101 ,  A61P35/00

公开(公告)号：EP4363448A1

公开(公告)日：2024-05-08

申请号：EP22747526.6

申请日：2022-06-29

申请人： Amgen Inc.

发明人： QI, Wei ,  REN, Cindy

IPC分类号： C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  A61P35/00

CPC分类号： C07K16/28 ,  C07K16/2809 ,  C07K16/2878 ,  C07K16/3092 ,  C07K2317/3120130101 ,  C07K2317/62220130101 ,  C07K2317/9420130101 ,  A61K39/39591 ,  A61P35/00

公开(公告)号：EP3388449A3

公开(公告)日：2018-10-24

申请号：EP17198468.5

申请日：2015-09-11

申请人： F. Hoffmann-La Roche AG

发明人： BHAKTA, Sunil ,  ERICKSON, Hans K. ,  JUNUTALA, Jagath R. ,  KOZAK, Katherine ,  OHRI, Rachana ,  PILLOW, Thomas

IPC分类号： C07K16/28 ,  C07K16/32 ,  C07K16/30 ,  C07K16/18 ,  A61P35/00

CPC分类号： C07K16/32 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6817 ,  A61K47/6849 ,  A61K47/6869 ,  A61K51/10 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/3069 ,  C07K16/3092 ,  C07K16/40 ,  C07K2317/40 ,  C07K2317/73 ,  C07K2317/94 ,  G01N33/582

摘要： Cysteine engineered antibodies comprising a free a cysteine at position 140 according to EU numbering in the heavy chain are generated. These antibodies are prepared by mutagenizing a nucleic acid sequence of a parent antibody to introduce a A140C mutation; expressing the cysteine engineered antibody; and isolating it.

公开(公告)号：EP3380117A1

公开(公告)日：2018-10-03

申请号：EP16867445.5

申请日：2016-11-23

申请人： Cartherics Pty. Ltd.

发明人： BOYD, Richard ,  TROUNSON, Alan ,  KAWAMOTO, Hiroshi

IPC分类号： A61K39/00 ,  A61K35/17 ,  C07K19/00 ,  C12N5/0783

CPC分类号： A61K39/001153 ,  A61K35/17 ,  A61K35/545 ,  A61K38/1774 ,  A61K39/001102 ,  A61K2039/5158 ,  A61P35/00 ,  C07K14/4748 ,  C07K14/7051 ,  C07K14/70517 ,  C07K16/2803 ,  C07K16/3092 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2506/45 ,  C12N2510/00

摘要： The present invention relates generally to a population of stem cells (e.g., iPSCs or HSCs) that comprise nucleic acids encoding a T cell receptor and a chimeric antigen receptor directed to multiple distinct antigenic determinants, for example two distinct tumour antigenic determinants. The present invention is also directed to a population of T cells that co-express a T cell receptor and a chimeric antigen receptor directed to multiple distinct antigenic determinants, such as two distinct tumour antigenic determinants. The cells of the present invention can be derived from chosen donors whose HLA type is compatible with significant sectors of the populations, and are useful in a wide variety of applications, in particular in the context of the therapeutic treatment of neoplastic conditions.

公开(公告)号：EP3350226A2

公开(公告)日：2018-07-25

申请号：EP16770571.4

申请日：2016-09-16

申请人： Prothena Biosciences Limited

发明人： LIU, Yue ,  GARIDEL, Patrick ,  LANGER, Andreas ,  FLANAGAN, Kenneth

IPC分类号： C07K16/30

CPC分类号： C07K16/3092 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92

摘要： The invention provides anti-MCAM antibodies that inhibit the ability of human MCAM to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica (PMR) or Takayasu's arteritis, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.

公开(公告)号：EP3307780A1

公开(公告)日：2018-04-18

申请号：EP16732438.3

申请日：2016-06-14

申请人： Genentech, Inc.

发明人： POLAKIS, Paul ,  DRAGOVICH, Peter ,  PILLOW, Thomas Harden ,  YU, Shang-Fan

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K39/00

CPC分类号： C07K16/30 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6889 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/3092 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/515

摘要： The invention provides immunoconjugates and methods of using the same.

公开(公告)号：EP2520590A8

公开(公告)日：2018-03-14

申请号：EP12163656.7

申请日：2008-04-03

申请人： Amgen Research (Munich) GmbH

发明人： Klinger, Matthias ,  Raum, Tobias ,  Rau, Doris ,  Mangold, Susanne ,  Kischel, Roman ,  Lutterbüse, Ralf ,  Hoffmann, Patrick ,  Kufer, Peter

IPC分类号： C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K16/42 ,  C07K16/46 ,  C07K14/725 ,  A61K39/395 ,  A61P35/00

CPC分类号： C07K16/2809 ,  A61K2039/505 ,  C07K16/082 ,  C07K16/109 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2878 ,  C07K16/2884 ,  C07K16/30 ,  C07K16/3053 ,  C07K16/3092 ,  C07K16/32 ,  C07K16/4291 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/40 ,  G01N33/566 ,  G01N33/57492 ,  G01N2500/00

摘要： The present invention relates to a polypeptide comprising a human binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 (epsilon) chain as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide. In a further aspect the invention provides a method for the identification of polypeptides comprising a cross-species specific binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3ε (CD3 epsilon).

摘要翻译： 本发明涉及包含能够结合人和非黑猩猩灵长类CD3（ε）链表位的人结合结构域的多肽以及生产所述多肽的方法。 本发明进一步涉及编码所述多肽的核酸，包含所述多肽的载体和包含所述载体的宿主细胞。 另一方面，本发明提供了包含所述多肽的药物组合物和该多肽的医学用途。 在另一方面，本发明提供了鉴定包含能够结合人和非黑猩猩灵长类CD3ε（CD3ε）的表位的跨物种特异性结合结构域的多肽的方法。

公开(公告)号：EP3271398A1

公开(公告)日：2018-01-24

申请号：EP16716959.8

申请日：2016-03-16

申请人： Memorial Sloan Kettering Cancer Center

发明人： SPRIGGS, David ,  FERNANDEZ-TEJADA, Alberto ,  THAPI, Dharmarao

IPC分类号： C07K16/30 ,  C12N15/13 ,  A61P35/00 ,  A61K39/395

CPC分类号： C07K16/3092 ,  A01K67/0275 ,  A01K2217/052 ,  A01K2217/15 ,  A01K2217/203 ,  A01K2227/105 ,  A01K2267/0331 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/4727 ,  C07K16/2809 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C12N2800/30

摘要： Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.

公开(公告)号：EP3150634A4

公开(公告)日：2018-01-03

申请号：EP15785665

申请日：2015-04-28

申请人： MEDICINAL CHEMISTRY PHARMACEUTICALS CO LTD

发明人： NISHIMURA SHINICHIRO ,  MIYOSHI RISHO ,  NARUCHI KENTARO ,  TANAKA MASAKAZU ,  SATO MASAHARU

IPC分类号： C07K16/30 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  C12P21/08 ,  C12Q1/02 ,  G01N33/574

CPC分类号： C07K16/3092 ,  C07K16/2896 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/76 ,  C12Q1/02 ,  G01N33/574 ,  G01N33/57492 ,  G01N2333/70596 ,  G01N2400/02

摘要： The present invention provides: an antibody exhibiting specificity for MUC1, the antibody having a glycan structure expressed at high levels in cancer cells; a method for manufacturing this antibody; and a novel means and method for the diagnosis and prevention and/or treatment of cancer using this antibody. The present invention is a monoclonal antibody to human MUC1, wherein the antibody specifically recognizes a glycopeptide having a human MUC1 tandem unit and furthermore having an O-linked glycan core (0(Tn)) in any one of the threonine and serine in the amino acid sequence of this human MUC1 tandem unit. A method for detecting MUC1 in a human body-fluid sample. A kit including this monoclonal antibody. A pharmacological composition for the prevention and/or treatment of a malignant tumor, the pharmacological composition containing this monoclonal antibody as an active ingredient.